Preemptive intravenous morphine-6-glucuronide is ineffective for postoperative pain relief.

Area of Science:

• Anesthesiology
• Pharmacology
• Pain Management

Background:

• Morphine-6-glucuronide (M-6-G) is a potent morphine metabolite, but its intravenous efficacy for pain is debated.
• Acute postoperative pain management requires effective analgesics.

Purpose of the Study:

• To evaluate the analgesic effectiveness of intravenous M-6-G for acute postoperative pain.
• To compare M-6-G with morphine and placebo in a randomized controlled trial.

Main Methods:

• 37 adult patients undergoing elective knee surgery were randomized into three groups: morphine, M-6-G, or placebo.
• Anesthesia was induced and maintained using standard agents.
• Postoperative pain was managed with patient-controlled analgesia, and side effects were monitored.

Main Results:

• No significant differences in patient characteristics or opioid-related side effects were observed between groups.
• Patients receiving M-6-G or placebo required significantly higher cumulative doses of morphine postoperatively compared to the morphine group.
• Morphine requirements were 41+/-9 mg (M-6-G), 49+/-8 mg (placebo), and 29+/-8 mg (morphine) in the first 24 hours.

Conclusions:

• A single intravenous dose of M-6-G was ineffective for treating acute postoperative pain.
• The limited efficacy may be due to M-6-G's poor blood-brain barrier permeability.